inamide:
Pyrazinamide may decrease the efficacy of gout therapy (e.g. allopurinol, colchicine, probenecid or sulphinpyrazone) and dosage adjustments of this medication may be necessary.
Ethambutol:
Concurrent administration of neurotoxic medication with ethambutol may potentiate neurotoxic effects such as optic and peripheral neuritis.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
For symptoms of overdosage, refer to "Side-Effects".
Treatment of overdosage consists of gastric lavage, symptomatic and supportive therapy.
IDENTIFICATION:
Purple, round, film coated tablets.
PRESENTATION:
Securitainers of 40, 60, 80, 100 and 500 tablets.
STORAGE INSTRUCTIONS:
Store in a cool place, below 25°C in well-closed containers, protected from light.
KEEP OUT OF REACH OF CHILDREN.
REGISTRATION NUMBER:
34/20.2.3/0187
NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Aventis Pharma (Pty) Ltd
2 Bond Street, Midrand, 1685
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
11 February 2002
Aventis Pharma (Pty) Ltd
2 Bond Street
Midrand
1685
RO2-A0003
Britepak
New addition to this site: April 2005
Source: Hospital Pharmacy
